From the Center for Outcomes and Policy Research, Department of Adult Oncology, Dana-Farber Cancer Institute; and Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA. (At 2000-09-18)
